These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32539683)

  • 1. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis.
    Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R
    BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
    Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
    Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
    [No Abstract]   [Full Text] [Related]  

  • 3. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
    Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
    Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary considerations in adjuvant radioiodine treatment of adults with differentiated thyroid cancer.
    Juweid ME; Tulchinsky M; Mismar A; Momani M; Zayed AA; Al Hawari H; Albsoul N; Mottaghy FM
    Int J Cancer; 2020 Nov; 147(9):2345-2354. PubMed ID: 32319676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.
    Ma C; Tang L; Fu H; Li J; Wang H
    Nucl Med Commun; 2013 Dec; 34(12):1150-6. PubMed ID: 24025918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
    Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
    Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
    Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer.
    Rosário PW; Barroso AL; Rezende LL; Padrão EL; Fagundes TA; Reis JS; Purisch S
    Ann Nucl Med; 2005 May; 19(3):247-50. PubMed ID: 15981681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
    Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
    James DL; Ryan ÉJ; Davey MG; Quinn AJ; Heath DP; Garry SJ; Boland MR; Young O; Lowery AJ; Kerin MJ
    JAMA Otolaryngol Head Neck Surg; 2021 Jun; 147(6):544-552. PubMed ID: 33792650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
    Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
    Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
    Bal CS; Kumar A; Pant GS
    Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
    Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
    Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.